Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 453-463

  Dixon, J Michael ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitor; Breast cancer; Exemestane; Letrozole; Neoadjuvant therapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE SULFATE; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; LETROZOLE; MEGESTROL ACETATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ALOPECIA; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CARDIOTOXICITY; CELL CYCLE ARREST; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG PREFERENCE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HOT FLUSH; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKORRHEA; MICROARRAY ANALYSIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PROGNOSIS; REVIEW; VAGINA BLEEDING; VAGINA DISCHARGE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR MODULATORS; FEMALE; FORECASTING; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; TUMOR MARKERS, BIOLOGICAL;

EID: 45249092092     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.453     Document Type: Review

References (69)

1. Consensus Statement: treatment of early-stage breast cancer. National Institutes of Health Consensus Development Panel. J. Natl Cancer Inst. Monogr. 11, 1-5 (1992).
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16(10), 1569-1583 (2005).
3. Mauriac L, Keshaviah A, Debled M et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG I-98 trial. Eur. J. Cancer Suppl. 4(2), 111 (2006) (Abstract 219).
4. McArthur HL, Olivotto I, Gelmon, KA et al. Risk of early relapse in postmenopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res. Treat. 94 (Suppl. 1), S124 (2005) (Abstract 3001).
5. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
6. Buzdar A, Valero V, Theriault RL et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res. Treat. 82(Suppl. 1), S69 (2003) (Abstract 302).
7. Gianni L, Zambetti M, Clark K et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23(29), 7265-7277 (2005).
8. Mamounas EP. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin. Oncol. 25, 31-35 (1998).
9. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur. J. Cancer 38(17), 2214-2221 (2002).
10. Beresford MJ, Ravichandran D, Makris A. Neoadjuvant endocrine therapy in breast cancer. Cancer Treat. Rev. 33(1), 48-57, (2007).
11. Gazet JC, Ford HT, Coombes RC et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur. J. Surg. Oncol. 20(3), 207-214 (1994).
12. Robertson JF, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 28A(4-5), 908-910 (1992).
13. Huober J, Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant endocrine therapy in primary breast cancer. Clin. Breast Cancer 5, 341-347 (2004).
14. Semiglazov VF, Semiglazov VV, Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer (2007) (Epub ahead of print).
15. Abrial C, Mouret-Reynier MA, Cure H et al. Neoadjuvant endocrine therapy in breast cancer. Breast 15(1), 9-19 (2006).
16. Murray J, Young O, Renshaw L et al. Letrozole and anastrozole: a pre-operative study of their effects on ER positive breast cancers in postmenopausal women. Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004 (Abstract 406).
17. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23, 5108-5116 (2005).
18. Banerjee S, Smith IE, Folkerd L et al.; IMPACT trialists. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann. Oncol. 16(10), 1632-1638 (2005).
19. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative "Arimidex" compared to tamoxifen (PROACT) trial. Cancer 106(10), 2095-2103 (2006).
20. Smith I, Cataliotti L. Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials. Eur. J. Cancer Suppl. 2, 47 (2004).
21. Eiermann W, Paepke S, Appfelstaedt J et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12, 1527-1532 (2001).
22. Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM. Is there an optimal duration of neoadjuvant letrozole therapy? Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004 (Abstract 405).
23. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9(Suppl. 2), 9-15 (2002).
24. Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane (E) versus tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). J. Clin. Oncol. 23(Suppl. 16), 11S (2005) (Abstract 530).
25. Krainick U, Astner A, Jonat W et al. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative (GENARI). Breast Cancer Res. Treat. 82(Suppl. 1), S55 (2003) (Abstract 239).
26. Tubiana-Hulin M, Spyratos F, Becette V et al. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer. Breast Cancer Res. Treat. 82(Suppl. 1), S106 (2003) (Abstract 443).
27. No authors listed. ACS surgical trial accrual campaign: get involved, make a difference. Bull. Am. Coll. Surg. 91(3), 51-52 (2006).
28. Paepke S, Tulusan A, Kiesel L et al. A multi-center study of pre-operative treatment with letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc. Am. Soc. Clin. Oncol. 22, 80 (2003) (Abstract 321).
29. Park D, Karesen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 451(1), 11-18 (2007).
30. Dowsett M, Smith IE, Ebbs SR et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res. 12(3), S1024-S1030 (2006).
31. Howell A, Cuzick J, Baum M et al. ATAC Trialists' Group. Results of the ATAC trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
32. Dowsett M, Smith IE, Ebbs SR et al; IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99, 167-170 (2007).
33. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER 1/2 expression status. Cancer Res. 63, 6523-6531 (2003).
34. Murray E, Renshaw L, Macaskill EJ et al. Factors predicting survival after neoadjuvant therapy with aromatase inhibitors. Breast Cancer Res. Treat. 100(Suppl. 1), S23 (2006) (Abstract 101).
35. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br. J. Cancer 94(7), 1051-1056 (2006).
36. Larionov A, Murray E, Evans DB, Miller WR, Dixon JM. Changes in cyclins and CDKs mRNA expression during neoadjuvant treatment with letrozole. Breast Cancer Res. Treat. 106(Suppl. 1), S280 (2007) (Abstract 6099).
37. Akashi-Tanaka S, Omatsu M, Shimizu C et al. Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast 16(5), 482-488 (2007).
38. Miller WR, Ellis MJ, Tao Y, Bhatnagar A, Evans DB, Sasano H. Absence of post treatment tumour expression of aromatase is associated with reduced antiproliferative effects of letrozole (but not tamoxifen) in the P024 adjuvant endocrine therapy trial. Breast Cancer Res. Treat. 100 (Suppl. 1), S186 (2006) Abstract 4045).
39. Miller WR, Renshaw L, Larionov A et al. Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. J. Clin. Oncol. 23(Suppl. 16), 198S (2005) (Abstract 3025).
40. Larionov A, Miller W, White S et al. High density micro-arrays do not accurately reflect the decrease in MKI67 in breast cancers during treatment with the aromatase inhibitors anastrozole and letrozole. Breast Cancer Res. Treat. 100(Suppl. 1), S221-S222 (2006) (Abstract 5026).
41. Dixon JM, Jackson J, Hills M et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur. J. Cancer 40(18), 2742-2747 (2004).
42. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin Oncol. 19, 3808-3816 (2001).
43. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur. J. Cancer 39(4), 462-468 (2003).
44. Young O, Murray J, Renshaw L et al Neoadjuvant letrozole is equally effective in Her 2 positive and negative breast cancers. Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004 (Abstract 411).
45. Ellis MJ, Tao Y, Young O et al. Estrogen-independent proliferation is present in estrogen-dependent HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. 24, 3019-3025 (2006).
46. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23, 5108-5116 (2005).
47. Thomas JSJ, Julian HS, Green RV, Cameron DA, Dixon JM. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology 51, 219-226 (2007).
48. Turner J, Bentey R, Tao Y et al. Changes in tumor grade with neoadjuvant endocrine therapy: morphological evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen. Presented at: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TY, USA, 8-11 December 2004 (Abstract 407).
49. kip1 in predicting enhanced autophagocytosis mi response to aromatase inhibitor therapy. Breast Cancer Res. Treat. 100(Suppl. 1), S187 (2006) (Abstract 4048).
50. Ellis MJ, Tao Y, Bhatnagar AS et al. Cell-cycle complete response after neoadjuvant letrozole predicts superior relapse-free and overall survival: long-term follow- up of the letrozole P024 study. J. Clin. Oncol. 25(Suppl. 18), S20 (2007) (Abstract 570).
51. Llombart A, Galán A, Fuster C et al. Phase II trial with letrozole (2.5mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Eur. J. Cancer Suppl. 4(2), 153 (2006) (Abstract 362).
52. Dixon JM, Renshaw L, Young O et al. Anastrozole and letrozole, an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res. Treat. 100(Suppl. 1), S24 (2006) (Abstract 105).
53. Renshaw L, McHugh RGN, Williams L et al. Comparison of joint problems reported by patients in a randomized adjuvant trial of anastrozole and letrozole. Breast Cancer Res. Treat. 106(Suppl.1), S108 (2007) (Abstract 2072).
54. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol. 18(22), 3758-3767 (2000).
55. Bonneterre J, Buzdar A, Nabholtz JM et al.; Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9), 2247-2258 (2001).
56. Mouridsen H, Gershanovich M, Monnier A et al; on behalf of the Letrozole P025 Brrast Cancer Study Group. Letrozole is superior to tamoxifen as first-line hormonal treatment of post-menopausal women with locally advanced or metastatic breast cancer (BC). Ann. Oncol. 11(Suppl. 4), 155 (2000) (Abstract 489).
57. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer results of a Phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol. 18(7), 1399-1411 (2000).
58. Mauriac L, Keshaviah A. Debled M et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol. 18(5), 859-867 (2007).
59. Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC ('Arimidex', tamoxifen, alone or in Combination) Trialists' group. Ann. Oncol. 17(Suppl. 9), ix94 (2006) (Abstract 243PD).
60. Baum M, Budzar AU, Cuzick J et al. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002). Erratum in: Lancet 360(9344), 1520 (2002).
61. Thürlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353(26), 2747-2457 (2005). Erratum in: N. Engl. J. Med. 354(20), 2200 (2006).
62. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350(11), 1081-1092 (2004). Erratum in: N. Engl J. Med. 351(23), 2461 (2004). N. Engl. J. Med. 355(16), 1746 (2006). van de Velde C [added].
63. Coombes RC, Kilburn LS, Snowdon CF et al; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561), 559-570 (2007). Erratum in: Lancet 369(9565), 906 (2007).
64. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349(19), 1793-1802 (2003).
65. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst. 97(17), 1262-1271 (2005).
66. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol. 24(Suppl. 18), S15 (2006) (Abstract 552).
67. Geisler J, Helle H, Ekse D et al. Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. J. Clin. Oncol. 24(Suppl. 18), S570 (2006) (Abstract 10532).
68. Monnier A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev. Anticancer Ther. 6(10), 1355-1359 (2006).
69. Jonat W, Mundhenke C. The FACE Trial: letrozole or anastrozole as initial adjuvant therap? Cancer Invest. 25(1), 14-18 (2007).